Spero Therapeutics, Inc. (SPRO) Total liabilities 2016–2025
Spero Therapeutics, Inc. (SPRO) total liabilities at each fiscal year-end, per SEC filings.
$9.9MFY2025 · since FY2016: $7.4M → $9.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $9.9M | -84.6% |
| FY2024 | $64.4M | -14.7% |
| FY2023 | $75.5M | +54.5% |
| FY2022 | $48.9M | -41.0% |
| FY2021 | $82.8M | +286.6% |
| FY2020 | $21.4M | -32.1% |
| FY2019 | $31.5M | +139.7% |
| FY2018 | $13.2M | +54.3% |
| FY2017 | $8.5M | +15.0% |
| FY2016 | $7.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Net marginSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating marginSPRO Operating cash flowSPRO Free cash flowSPRO Capital expendituresSPRO Return on equitySPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Shareholders’ equitySPRO overview →